Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients

Abstract

PURPOSE: Previous reports have suggested that polymorphism in the vitamin D receptor (VDR) gene is associated with sporadic breast cancer, but there is controversy among different authors and ethnic groups. The purpose of this study was to determine whether polymorphism in the VDR gene might also influence breast cancer risk in Taiwan, a country with a low incidence of breast cancer.

METHODS: Polymorphisms in the end of the VDR gene were genotyped for 34 Taiwanese women with sporadic breast cancer, 46 with benign breast tumors and 169 cancer-free female cohort controls.

RESULTS: The ApaI, TaqI, and BsmI polymorphisms in the 3' end of the VDR gene were associated with breast cancer risk, with a trend for increasing risk with increased numbers of BsmI B alleles and ApaI AA genotypes. When the allele frequencies of BsmI polymorphism were compared among the three populations, a significant difference was observed (chi2 = 13.684, df = 4, p = 0.0084). The OR of the Aa genotype was 0.333 (95% CI = 0.1 14-0.978) and that of the aa genotype was 0.515 (95% CI = 0.190-1.398). These data indicate that the AA genotype may be associated with an increased risk of breast cancer, while the Aa genotype tends to be associated with decreased risk. The TaqI polymorphism was not associated with breast cancer risk in this study.

CONCLUSION: These results suggest that polymorphic variation in or near the 3' end of the VDR gene may influence breast cancer risk in Taiwanese women and justifies further investigation of the role of VDR for sporadic breast cancer in low-incidence areas. These findings also should help when designing targeted therapy.

About this publication.

See also:

- Vitamin D (analogues and/or derivatives) and cancer;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature.